Jinwu Financial News | Hewong Pharmaceutical (00013) rebounded against the market at the beginning of the session. As of press release, it rose 5.76% to HK$23.85, with a turnover of HK$94.2265 million.
The company announced that the combination therapy of ORPATHYS (ORPATHYS, savolitinib) and osimertinib (TAGRISSO, osimertinib) (TAGRISSO, osimertinib) is used to treat EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients with MET amplification who have progressed after receiving first-line epidermal growth factor receptor (EGFR) inhibitors.
According to reports, Warisal is a potent and highly selective oral MET tyrosine kinase inhibitor (TKI). Teresa is an irreversible third-generation EGFR TKI.
